https://www.selleckchem.com/pr....oducts/n6-methyladen
onent, significantly increases the level of pain threshold and improves the disability of patients in 3 months after the start of treatment. To study the efficacy and safety of sequential MexidoL therapy, administered intravenously (500 mg once a day) for 14 days, followed by taking the oral form Mexidol FORTE 250 at a dose of 250 mg (1 tablet) 3 times a day for 60 days in elderly patients with chronic cerebral ischemia (CCI) on the background of arterial hypertension and atherosclerosis. An open prospective observational stu
Like
Comment
Share
